Publications

VTx-001 – ALS treatment

  • ALS/MND presentation - Duarte et al (2025) VTx-001: A vectorized antibody for ALS targeting PC-OxPL

  • ESGCT poster - Gomes-Duarte et al (2025) AAV-Delivered Anti-PC-OxPL Antibody Fragments: A Novel Therapeutic Approach to Target ALS

  • Lipids in Brain Diseases Symposium presentation - Duarte et al (2025) VTx-001: A vectorized antibody for ALS targeting PC-OxPL

  • Lipids in Brain Diseases Symposium poster - Haselberg et al (2025) Targeting oxidized phosphatidylcholines in SOD1-associated ALS: therapeutic potential of PC-OxPL-VecTab

  • VTx-001 publication – Gomes-Duarte et al (2025) Targeting oxidized phosphatidylcholines in SOD1-associated ALS: therapeutic potential of PC-OxPL-VecTab

  • VTx-001 publication – Gomes-Duarte et al (2025) AAV-delivered anti-PC-OxPL antibody fragments: a novel therapeutic approach to target ALS

  • Target ALS poster – Gomes-Duarte et al (2025) AAV-delivered anti-PC-OxPL antibody fragments: a novel therapeutic approach to target ALS

VTx-002 – ALS treatment

  • ALS/MND poster - Uspenskaya et al (2025) Non-clinical development and Phase 1/ 2 clinical trial design of VTx-002, an AAV5.2 vectorized intrabody targeting TDP-43 for Amyotrophic Lateral Sclerosis

  • ENCALS poster - de Sabbata et al (2025) AAV-mediated intrabody therapy targeting TDP-43 proteinopathy in ALS

  • MNDA poster - Sogorb et al. (2022) VecTabs® and advanced human in-vitro models: Targeting TDP-43 aggregates and oxidized phosphocholines in amyotrophic lateral sclerosis

  • ASGCT poster – Miranda et al (2025) AAV-mediated delivery of an intrabody targeting TDP-43 for Amyotrophic Lateral Sclerosis therapy

VTx-003 - HD treatment

  • ESGCT poster - Sogorb-Gonzalez et al. (2025) Targeting misfolded mutant HTT protein with vectorized antibodies for the treatment of Huntington Disease

  • DHDRN presentation - Konstantinova (2023), Precision targeted therapies for neurodegenerative diseases

  • HDF poster - Pasteuning et al. (2022), VecTabs®: Targeting misfolded and aggregated proteins with vectorized antibodies for the treatment of ALS and HD

  • ASGCT poster – Duarte, et al (2025) Targeting misfolded mutant HTT protein with vectorized antibodies for the treatment of Huntington Disease

Platform technology

  • ESGCT Poster - Spits et al. (2022), Gene Therapy Mediated Targeted Protein Degradation in Neurodegenerative Disease Models

  • ESGCT poster - Gallego et al. (2022), Next generation rAAV capsids show enhanced transduction efficiency in 2D and 3D human cellular models for neurodegenerative diseases

  • ASGCT poster – Puri et al (2025) An Optimized Baculovirus Generation Process and Novel ITR-Transgene Design for High Quality AAV Production Using the Insect Cell Production Platform